Medtronic announces early data for the intrepid™ transcatheter mitral valve replacement (tmvr) system using new transfemoral delivery system

Transfemoral access added into landmark apollo pivotal trial following ide approval from fda dublin and orlando, fla., nov. 6, 2021 /prnewswire/ -- medtronic plc (nyse:mdt), a global leader in healthcare technology, today presented early data for its self-expanding intrepid™ transcatheter mitral valve replacement (tmvr) system in patients with severe, symptomatic mitral valve regurgitation (mr) utilizing the transfemoral access route.
MDT Ratings Summary
MDT Quant Ranking